ALK NSCLC treatment, ‘Zykadia’ will be applied for insurance benefit

Published: 2016-07-25 16:26:00
Updated: 2016-07-25 15:35:32

As approved in the health insurance benefit, another ALK(Anaplastic Lymphoma Kinase) positive non-small cell lung cancer treatment can now be clinically used.

In the ‘Announced Amendment on Drugs Prescribed for Cancer Patients’ recently revealed by the Health Insurance Review & Assessment Servic...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.